As adeno-associated virus (AAV)-based gene therapies are being increasingly approved for
use in humans, it is important that we understand vector–host interactions in detail. With the …

Recombinant adenovirus-associated (rAAV) vectors due to their ease of construction, wide
tissue tropism, and lack of pathogenicity remain at the forefront for long-term gene …

Introduction Altering the human genetic code has been explored since the early 1990s as a
definitive answer for the treatment of monogenic and acquired diseases which do not …

Advances in adeno-associated virus (AAV) engineering have provided exciting new tools for
research and potential solutions for gene therapy. However, the lung has not received the …

Viral vector mediated gene therapy has become commonplace in clinical trials for a wide
range of inherited disorders. Successful gene transfer depends on a number of factors, of …

Gene therapy of genetically determined diseases, including some pathologies of the
respiratory system, requires an efficient method for transgene delivery. Recombinant adeno …

Background Neutrophilic asthma (NA) may result in irreversible airflow limitations. Soluble
advanced glycosylation receptor (sRAGE) has been shown to be associated with …

ABSTRACT Human bocavirus 1 (HBoV1) is a parvovirus that gathers increasing attention
due to its pleiotropic role as a pathogen and emerging vector for human gene therapy …

Recombinant adeno-associated virus (rAAV) vector platforms have shown considerable
therapeutic success in gene therapy for inherited disorders. In cystic fibrosis (CF) …

Abstract Adeno-Associated Virus (AAV) is a non-pathogenic virus that has been harnessed
as a vector system for therapeutic gene transfer. Despite decades of research on AAV as a …